Filing Flows › Celularity (CELU) › Q3 2025
Celularity (CELU) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
Celularity (CELU) reported revenue of $5.3M for the third quarter 2025 (Q3 2025), -43% from a year earlier and -8% from the quarter before. Operating margin was -244.1%, net loss $23.1M (436.7% of revenue).
Celularity, Q3 2025: revenue $5.3M (-43% year over year), operating margin -244.1%, net loss $23.1M, operating cash flow −$4.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.3M | -8% | -43% |
| Operating profit | −$12.9M | — | — |
| Net earnings | −$23.1M | — | — |
| Operating cash flow | −$4.2M | — | — |
What changed
Revenue was $5.3M in Q3 2025, down 43% year over year and down 8% from the previous quarter. License, Royalty and Other was the largest line at 56% of revenue. Product lost $2.5M year over year (down 74%), 62% of the total change.
Operating costs exceeded revenue by $12.9M, an operating margin of -244.1%. Total costs fell 13% while revenue fell 43%. The fastest-growing cost line was Research & development (+17%). The quarter ended with a net loss of $23.1M, narrower than the previous quarter's $24.5M loss.
Operating cash flow was −$4.2M. Non-cash charges added back $1.8M of depreciation and amortization and $471K of share-based compensation. Working capital and other items added $16.6M.
Questions
What was Celularity's revenue in the third quarter 2025?
Celularity (CELU) reported revenue of $5.3M for the third quarter 2025 (Q3 2025), -43% from a year earlier and -8% from the quarter before.
Was Celularity profitable in the third quarter 2025?
Operating loss was $12.9M (-244.1% of revenue) and net loss $23.1M.
Source: Celularity 10-Q on SEC EDGAR.